Skip to content
Search

Latest Stories

Gender identity services: GPhC publishes new resource for pharmacy professionals

Gender identity services: GPhC publishes new resource for pharmacy professionals

The regulatory body sets out questions that pharmacy professionals should ask themselves when providing gender identity care 

The General Pharmaceutical Council (GPhC) has produced a new resource to support pharmacists and pharmacy technicians who are providing pharmacy services to children and young people with gender incongruence or dysphoria.


It emphasises that pharmacy teams providing such services need to adhere to the standard process of clinical assessment and care provision they have been trained to take as healthcare professionals.

The starting point is that pharmacy professionals must provide compassionate, inclusive and person-centred care, within the current relevant legal and regulatory context.

“It’s essential that all patients have access to appropriate, high-quality and respectful healthcare, free from discrimination or bias,” the GPhC noted.

The GPhC observed that recent developments, such as the release of the final Cass report and various national policy updates, have raised complex questions for pharmacy professionals about prescriptions for puberty suppressing hormones, cross-sex hormones and related medicines for children and young people.

Although pharmacists are not expected to be prescribing in this context, the regulatory body recognises that there may be challenges and questions associated with the supply of medicines.

Earlier, the GPhC set out several issues to consider when providing any services to children and young people presenting with gender identity issues.

This time, it has outlined the associated questions that pharmacy professionals should consider when making decisions about the supply of medicines in this context, applicable to both in-person and online service provisions.

NHS England has commissioned an independent review, led by Dr Hilary Cass, to examine assessment, diagnosis, and care provision for children and young people presenting with gender identity issues. The review, currently underway, aims to offer guidance for the future of services in England.

More For You

NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less
AAH upgrades ordering portal, making procurement easier for pharmacies

AAH Cascade compares prices and availability across suppliers

AAH Warehouse

AAH upgrades ordering portal to improve product visibility

Leading pharmaceutical wholesaler AAH Pharmaceuticals Ltd has introduced new digital functionalities to AAH Cascade, its independently managed ordering portal, making procurement easier and more cost-effective for pharmacies.

AAH Cascade compares product prices and availability across multiple suppliers, eliminating the need for manual searches.

Keep ReadingShow less
Majority of Brits neglect consistent skincare routine,  survey finds

On average, Brits go to bed without washing their face twice a week.

Photo credit: gettyimages

Skincare: One in five Brits go to bed without washing their face daily, survey finds

Nearly two-thirds of Brits (60 per cent) neglect a consistent skincare routine,with almost one in five going to bed without washing their face daily, according to a new survey by consumer health company Kenvue.

The UK-wide survey of 2,000 people revealed that one-third of respondents (34 per cent) spend five minutes or less on their daily skincare routine. On average, Brits go to bed without washing their face twice a week.

Keep ReadingShow less
Risk of pharmacy closures remains despite record funding uplift

Community pharmacy sector remains in a fragile position as the funding gap is still significant, says CCA.

gettyimages

Pharmacy closures still a risk as funding deal fails to cover costs – warns CCA

The community pharmacy sector has secured the largest funding uplift across the NHS, yet concerns remain that it may not be enough to prevent further closures and service reductions.

Following a six-week consultation with Community Pharmacy England (CPE), the government has approved a £3.073 billion funding package for 2025/26, supplemented by an additional £215 million to support Pharmacy First and other Primary Care Recovery Plan services.

Keep ReadingShow less